Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development

Beta Bionics (Nasdaq: BBNX) updated expectations for Mint, its ACE insulin patch pump in development.

Rhea-AI Summary

Beta Bionics (Nasdaq: BBNX) updated expectations for Mint, its ACE insulin patch pump in development. The company now anticipates full commercialization by the end of Q2 2027, subject to FDA 510(k) clearance, and reports progress scaling manufacturing to meet anticipated launch demand.

Planned features include compatibility with Beta Bionics’ FDA-approved iAGC algorithm, leading CGMs, smartphone control, three-day wear, 200-unit reservoir, waterproofing, pharmacy-only availability, and a reusable/disposable design to limit environmental waste.

Positive

• Target for full Mint commercialization by end of Q2 2027, pending FDA clearance
• Manufacturing scale-up expected to meet anticipated Mint launch demand
• Mint designed to work with FDA-approved fully adaptive iAGC algorithm
• Planned compatibility with Dexcom G7, G7 15 Day, and FreeStyle Libre 3 Plus
• Pharmacy-only distribution leverages existing iLet market access agreements
• Two-piece reusable/disposable design aimed at limiting environmental waste

Negative

• Mint commercialization remains contingent on FDA 510(k) regulatory clearance
• Mint device not yet cleared or available for sale to patients
• Actual Mint product specifications and features may differ at launch

Argus May 22 session

+11.40% close to close Open Argus

Details

News Market Reaction – BBNX

On May 22, the first trading day after this news, BBNX closed 11.40% above the previous close.

Data tracked by StockTitan Argus for the May 22 session.

Key Figures

Commercialization target: End of Q2 2027 Insulin reservoir: 200 units Wear time: 3 days +1 more

Commercialization target

End of Q2 2027

Expected full commercialization timing for Mint, subject to FDA clearance

Insulin reservoir

200 units

Mint patch pump insulin capacity at expected commercialization

Wear time

3 days

Expected Mint patch pump wear duration per use

Grace period

12 hours

Additional wear-time grace period after the initial 3 days

Historical Context

5 past events · Latest: Apr 27

5 events

1. Apr 27

   Conference appearance

   24h Move

   -5.3%

   Announcement of participation in Bank of America health care conference webcast.

2. Apr 21

   Earnings & guidance

   24h Move

   -4.4%

   Q1 2026 results and raised full-year 2026 revenue and margin guidance.

3. Mar 31

   Product feature launch

   24h Move

   +1.6%

   Launch of Bionic Insights to enhance clinician interpretation of iLet data.

4. Mar 30

   Earnings date notice

   24h Move

   +1.6%

   Scheduling announcement for upcoming Q1 2026 earnings release and call.

5. Feb 19

   Conference appearance

   24h Move

   +1.8%

   Disclosure of management presentation at TD Cowen health care conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

alternate controller enabled (ace) insulin pump, 510(k) application, interoperable automated glycemic controller (iagc), continuous glucose monitors, +1 more

5 terms

alternate controller enabled (ace) insulin pump medical

"Mint alternate controller enabled (ACE) insulin pump 510(k) application"

An alternate controller enabled (ACE) insulin pump is a pump built to allow separate approved devices or software to remotely change insulin delivery, enabling third-party apps or glucose sensors to act as the “brain” that adjusts dosing. For investors, ACE status matters because it opens the device to broader ecosystems, partnerships and software-driven features that can boost adoption, create new revenue streams and change regulatory or liability profiles.

510(k) application regulatory

"FDA’s initial responses to the company’s Mint ... insulin pump 510(k) application"

A 510(k) application is a regulatory submission to the U.S. Food and Drug Administration showing that a new medical device is substantially similar to an already approved device, so it can be cleared for marketing without the longest, most rigorous approval process. For investors, a cleared 510(k) means faster, lower-cost market access and lower regulatory risk compared with full approvals, which can speed revenue and reduce uncertainty — like getting permission to sell a new model because it’s close to an existing one.

interoperable automated glycemic controller (iagc) medical

"compatible with Beta Bionics’ proprietary and FDA-approved interoperable automated glycemic controller (iAGC)"

An interoperable automated glycemic controller (iagc) is a medical system that automatically adjusts insulin delivery by linking a continuous glucose monitor, an insulin pump, and a control algorithm that can work with devices from different manufacturers. For investors, iagcs matter because they can expand the diabetes device market, speed adoption and recurring revenue through software and services, and carry regulatory and reimbursement implications that influence company value.

continuous glucose monitors medical

"Compatible with industry-leading continuous glucose monitors: Dexcom G7..."

A continuous glucose monitor is a small wearable device with a sensor placed just under the skin that measures blood-sugar levels around the clock and sends those readings to a display or smartphone — like a fitness tracker for glucose. Investors care because adoption and repeat purchases of sensors and supplies create steady revenue, while clinical usefulness, pricing, insurance coverage and regulatory approval determine how fast and widely the devices sell.

patch pump medical

"Mint™, its Patch Pump in Development"

A patch pump is a small, wearable insulin delivery device that sticks to the skin and automatically delivers measured doses of insulin throughout the day; it usually pairs with a remote controller or smartphone app so users can adjust doses without carrying a traditional pump. For investors, patch pumps matter because they target a large, growing market for diabetes care, create recurring revenue from disposable patches and supplies, and face value swings tied to regulatory approvals, reimbursement rules and adoption by patients and clinicians.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA). The updated Mint commercialization timeline expectation is based on the FDA’s initial responses to the company’s Mint alternate controller enabled (ACE) insulin pump 510(k) application, and the progress the company has made in scaling its Mint manufacturing processes. The company expects manufacturing capacity to meet anticipated demand at launch.

“We believe that Mint, which stands for Mini Insulin Therapy, will represent a meaningful advancement for people with diabetes,” said Sean Saint, President & CEO of Beta Bionics. “In pairing our fully adaptive insulin dosing algorithm with Mint, subject to regulatory clearance, we expect to deliver an innovation to the market that expands choice of form factor for our existing customers, and choice of insulin dosing algorithm for existing and prospective patch pump users.”

The image shown is for illustrative purposes only. Actual product specifications may vary.

Mint Features Expected at the Time of Commercialization*

• Similar size compared to the industry-leading patch pump
• Compatible with Beta Bionics’ proprietary and FDA-approved interoperable automated glycemic controller (iAGC), the first and only fully adaptive insulin dosing algorithm, and the most advanced insulin dosing algorithm available in the United States¹
• Compatible with industry-leading continuous glucose monitors: Dexcom G7, Dexcom G7 15 Day, and Abbott’s FreeStyle Libre 3 Plus
• iOS and Android smartphone controlled
• Never requires recharging
• No phone required during the Mint disposable patch change process
• 200-unit insulin reservoir
• Three days of wear time, with an additional 12-hour grace period
• Waterproof for showering and swimming
• Exclusively available in the pharmacy channel; ability to leverage existing market access footprint and agreements for iLet in the pharmacy channel to build pharmacy coverage for Mint
• Two-piece reusable and disposable architecture designed to limit environmental waste
  

*Commercialization of the Mint patch pump is subject to regulatory clearance, and the device is not available for sale. Actual product specifications and features may vary.

1.  Cook, K., et.al (2025). Defining the Automated Insulin Delivery Continuum: User Engagement and System Adaptation. ADCES 2025. Poster Presentation, 2025 Aug 9

More details will be shared when FDA clearance is secured.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding, the timing or certainty of the FDA’s approval of Mint as an ACE insulin pump, and the timing or certainty of commercialization of Mint and related updates; the Company’s manufacturing capacity at launch; Mint’s potential benefits for people with diabetes; the anticipated specifications and features for Mint; and the Company’s ability to leverage existing iLet market access footprint and agreements for iLet in the pharmacy channel to build pharmacy coverage for Mint. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Source: Beta Bionics, Inc.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/dd9f136d-aea8-46b4-8bfa-63568d4bc933

https://www.globenewswire.com/NewsRoom/AttachmentNg/4719df89-36b7-46eb-acbf-732b33220499

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Beta Bionics (BBNX) expect to commercialize the Mint patch pump?

Beta Bionics expects to fully commercialize Mint by the end of Q2 2027, subject to FDA clearance. According to Beta Bionics, this updated timeline reflects initial FDA feedback on its 510(k) submission and progress in scaling Mint manufacturing capacity.

What is the Mint patch pump from Beta Bionics (BBNX)?

Mint is a patch insulin pump in development, designed for Mini Insulin Therapy. According to Beta Bionics, Mint is expected to pair with its FDA-approved iAGC adaptive insulin dosing algorithm, offering an additional form factor option for automated insulin delivery users.

Which devices will the Beta Bionics (BBNX) Mint patch pump be compatible with?

Mint is expected to be compatible with Beta Bionics’ iAGC algorithm and leading CGMs. According to Beta Bionics, planned CGM compatibility includes Dexcom G7, Dexcom G7 15 Day, and Abbott FreeStyle Libre 3 Plus, plus iOS and Android smartphone control.

What key features are planned for the Mint patch pump from Beta Bionics (BBNX)?

Planned Mint features include a 200-unit reservoir, three-day wear, and waterproofing for showering and swimming. According to Beta Bionics, Mint is also expected to be smartphone controlled, never require recharging, and use a reusable/disposable design to reduce waste.

How will Beta Bionics (BBNX) distribute the Mint patch pump once commercialized?

Mint is expected to be available exclusively through the pharmacy channel. According to Beta Bionics, this allows the company to leverage existing market access and agreements for its iLet system to build pharmacy coverage for Mint after regulatory clearance.

Is the Mint patch pump from Beta Bionics (BBNX) already FDA cleared or on the market?

Mint is not yet FDA cleared and is not available for sale. According to Beta Bionics, commercialization remains subject to FDA 510(k) clearance, and actual Mint specifications and features may differ from current expectations at the time of launch.